2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.Peer-Reviewed Original ResearchConceptsRecurrent malignant gliomaDose-limiting toxicityMTOR inhibitor temsirolimusMalignant gliomasAkt inhibitor perifosinePhase I clinical trialDose level 3Dose level 7Phase II doseSynergistic anti-tumor effectKarnofsky performance statusPhase I trialDeadly primary brain cancerPI3K/Akt/mTOR axisPrimary brain cancerAkt/mTOR axisAnti-tumor effectsPotential therapeutic targetMost malignant gliomasPrior therapyTemsirolimus dosePerformance statusI trialIntracerebral hemorrhageCombined therapy
2016
Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas
Rizzitano S, Cavanè A, Piazzoni M, Vendramin A, Gimondi S, Biancon G, Malan S, Dodero A, Corradini P, Carniti C. Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas. Blood 2016, 128: 3967. DOI: 10.1182/blood.v128.22.3967.3967.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaT cell receptorChou-Talalay combination indexDose-dependent mannerCell cycle distributionFlow cytometryCell cycle arrestC-myc expressionPreclinical modelsTK inhibitorsCell linesLeukemia cell linesInhibitor dasatinibC-MycWestern blottingG1 populationGene expression profilingSynergistic anti-tumor effectBET inhibitorsLong-term remissionG0/G1 phase arrestStem cell transplantationSynergistic anti-tumor efficacyMitochondrial depolarization
2015
Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.Peer-Reviewed Original ResearchResidual MM cellsDegradation of IKZF1MM cellsClonogenic growthRNAi-mediated inhibitionHDAC inhibitorsMyeloma cellsResidual myeloma cellsSynergistic anti-tumor effectImmune-modulatory drugsHuman MM cellsPrimary MM cellsAnti-myeloma effectTrichostatin AMM plasma cellsAnti-tumor effectsMM cell linesAnti-proliferative effectsConcurrent therapyImmunomodulatory drugsResidual diseaseModulatory drugsPlasma cellsT cellsRecent studies
2013
Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).
Kaley T, Pentsova E, Omuro A, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis L, Lacouture M, Holland E, Lassman A. Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG). Journal Of Clinical Oncology 2013, 31: 2095-2095. DOI: 10.1200/jco.2013.31.15_suppl.2095.Peer-Reviewed Original ResearchRecurrent malignant gliomaPhase I trialMalignant gliomasI trialDose level 3Dose level 7Dose of temsirolimusMedian age 52Progressive malignant gliomaSynergistic anti-tumor effectPI3K/Akt/mTOR signalingAkt/mTOR SignalingMTOR inhibitor temsirolimusAnti-tumor effectsPotential therapeutic targetKPS 80Prior RTPrior therapyLimiting toxicitiesIntracerebral hemorrhageCombined therapyCombination therapyPreclinical dataLung infectionCell cycle arrest
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply